Literature DB >> 11078359

Endothelins are angiogenic.

E L Bek1, M A McMillen.   

Abstract

Endothelins-1 and 3 (ET-1 and 3) were evaluated for angiogenesis in the rat cornea. Bisected 2 mm pellets containing 20-1000 ng of ET-1 or ET-3 in Hydron were placed in corneal micro-pockets. Murine vascular endothelial growth factor (VEGF) and human interleukin-8 (IL-8) were positive controls. No angiogenesis occurred in 32 corneas with pellets containing only saline. With 200 ng VEGF pellets, 27/52 corneas (52%) demonstrated angiogenesis. With 200 ng IL-8 pellets, 32/51 corneas (63%) demonstrated angiogenesis. With 20-1000 ng ET-1 pellets, angiogenesis occurred in 65/91 corneas (71%); with ET-3 pellets, 84/116 (72%). ET-1- and ET-3-mediated angiogenesis was unaffected by cyclophosphamide-induced leukopenia. ET-1-mediated angiogenesis was inhibited by an ET(A)-receptor antagonist (ra) (BQ610) and a combined ET(A)/ET(B) ra (bosentan). However, ET-1-mediated angiogenesis was not inhibited by an ET(B) ra(BQ788) and a weak ET(A) ra(BQ123). Thus, ET-1 and -3 are angiogenic in the rat cornea; this effect appears to be direct, not leukocyte-mediated, and ET(A)-receptor-dependent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11078359     DOI: 10.1097/00005344-200036051-00043

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  17 in total

1.  Thrombin-induced endothelin-1 synthesis and secretion in retinal pigment epithelial cells is rho kinase dependent.

Authors:  Santosh Narayan; Ganesh Prasanna; Kissaou Tchedre; Raghu Krishnamoorthy; Thomas Yorio
Journal:  J Ocul Pharmacol Ther       Date:  2010-10       Impact factor: 2.671

2.  Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis.

Authors:  Longwei Qiao; Yuting Liang; Na Li; Xiaoxia Hu; Dongwei Luo; Junxia Gu; Yaojuan Lu; Qiping Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

3.  Endothelin-1 overexpression: a potential biomarker of unfavorable prognosis in non-metastatic muscle-invasive bladder cancer.

Authors:  Lampros Mitrakas; Stavros Gravas; Foteini Karasavvidou; Georgios Dimakopoulos; Georgios Moutzouris; Vasileios Tzortzis; Georgios Koukoulis; Christos Papandreou; Michael Melekos
Journal:  Tumour Biol       Date:  2015-01-28

4.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

Review 5.  Medical therapies for meningiomas.

Authors:  Patrick Y Wen; Eudocia Quant; Jan Drappatz; Rameen Beroukhim; Andrew D Norden
Journal:  J Neurooncol       Date:  2010-09-04       Impact factor: 4.130

6.  Responses of cultured human keratocytes and myofibroblasts to ethyl pyruvate: a microarray analysis of gene expression.

Authors:  Stephen A K Harvey; Emily Guerriero; Nahthai Charukamnoetkanok; Jordan Piluek; Joel S Schuman; Nirmala Sundarraj
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-06       Impact factor: 4.799

7.  Molecular biology of unreresectable meningiomas: implications for new treatments and review of the literature.

Authors:  Jay Jagannathan; Rod J Oskouian; Hian Kwang Yeoh; Dwight Saulle; Aaron S Dumont
Journal:  Skull Base       Date:  2008-05

8.  Effects of Controlled Cortical Impact on the Mouse Brain Vasculome.

Authors:  Shuzhen Guo; Josephine Lok; Song Zhao; Wendy Leung; Angel T Som; Kazuhide Hayakawa; Qingzhi Wang; Changhong Xing; Xiaoying Wang; Xunming Ji; Yiming Zhou; Eng H Lo
Journal:  J Neurotrauma       Date:  2016-02-12       Impact factor: 5.269

Review 9.  Novel aspects of corneal angiogenic and lymphangiogenic privilege.

Authors:  David Ellenberg; Dimitri T Azar; Joelle A Hallak; Faisal Tobaigy; Kyu Yeon Han; Sandeep Jain; Zhongjun Zhou; Jin-Hong Chang
Journal:  Prog Retin Eye Res       Date:  2010-01-25       Impact factor: 21.198

10.  Endothelin-1 role in human eye: a review.

Authors:  Serena Salvatore; Enzo Maria Vingolo
Journal:  J Ophthalmol       Date:  2011-03-03       Impact factor: 1.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.